Autochecked users, Comment administrators, Editors, Interface administrators, Reviewers, Suppressors, Administrators, Widget editors
1,876
edits
Changes
HAEM5:Hyperplasias arising in immune deficiency/dysregulation (view source)
Revision as of 14:27, 13 December 2023
, 14:27, 13 December 2023no edit summary
<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|encompassing non-destructive post-transplant lymphoproliferative disorders, among others
<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|encompassing non-destructive post-transplant lymphoproliferative disorders, among others
}}</blockquote>
}}</blockquote>
<span style="color:#0070C0">(General Instructions – The main focus of these pages is the clinically significant genetic alterations in each disease type. Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/ HGVS-based nomenclature for variants], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples). Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see </span><u>[[Author_Instructions]]</u><span style="color:#0070C0"> and [[Frequently Asked Questions (FAQs)|<u>FAQs</u>]] as well as contact your [[Leadership|<u>Associate Editor</u>]] or [mailto:CCGA@cancergenomics.org <u>Technical Support</u>])</span>
==Primary Author(s)*==
==Primary Author(s)*==